The recombinant protein alefacept (Amevive®) is an immunomodulator approved for the treatment of moderate to severe chronic plaque psoriasis. In phase 3 clinical studies, treatment of psoriatic patients with alefacept at a safe and well-tolerated dose caused meaningful reductions in psoriasis area and severity index and in physician global assessment scores as well…